ia, including those with heterozygous familial hypercholesterolemia (hefh). the effects of evkeeza on cardiovascular morbidity and mortality have not been determined.

nd monitor until signs and symptoms resolve. evkeeza is contraindicated in patients with a history of serious hypersensitivity reaction to evinacumab-dgnb [see contraindications (4) ]. 5.2 embryo-fetal toxicity based on the findings in animal reproduction studies, evkeeza may cause fetal harm when administered to pregnant patients. administration of evinacumab to rabbits during organogenesis caused increases in fetal malformations at doses below the human exposure. advise patients who may become pregnant of the risk to a fetus. consider obtaining a pregnancy test prior to initiating treatment with evkeeza. advise patients who may become pregnant to use effective contraception during treatment with evkeeza and for at least 5 months following the last dose of evkeeza [see use in specific populations (8.1 , 8.3) ] .

te of the last dose. assess ldl-c when clinically appropriate. the ldl-lowering effect of evkeeza may be measured as early as 2 weeks after initiation. 2.2 preparation instructions for intravenous infusion calculate the dose (mg), total volume (ml) of evkeeza required, and the number of vials required based on the patient's current body weight. visually inspect the solution for cloudiness, discoloration, and particulate matter prior to administration. evkeeza is a clear to slightly opalescent, colorless to pale-yellow solution. do not administer if the solution is cloudy or discolored or contains particulate matter. evkeeza vials are single-dose containers and do not contain a preservative. observe aseptic technique when preparing evkeeza. do not shake the vial. withdraw the required volume from the vial(s) of evkeeza and transfer into an iv infusion bag containing a maximum volume of 250 ml of 0.9% sodium chloride injection, usp or 5% dextrose injection, usp. mix the diluted solution by gentle inversion; do not shake. the final concentration of the diluted solution should be between 0.5 mg/ml and 20 mg/ml depending on the patient's current body weight. administer the diluted solution immediately after preparation and discard any unused portion left in the vial. if not used immediately, store the diluted solution refrigerated at 2 °c to 8 °c (36 °f to 46 °f) for no more than 24 hours from the time of preparation or at room temperature up to 25 °c (77 °f) for no more than 6 hours from the time of infusion preparation to the end of the infusion. do not freeze the diluted solution. 2.3 administration instructions for intravenous infusion if refrigerated, allow the diluted solution to come to room temperature prior to administration. administer evkeeza diluted solution via iv infusion over 60 minutes through an iv line containing a sterile, in-line or add-on, 0.2-micron to 5-micron filter. do not mix other medications with evkeeza or administer other medications concomitantly via the same infusion line. the rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion or hypersensitivity reactions [see warnings and precautions (5.1) and adverse reactions (6.1) ]. evkeeza can be administered without regard to the timing of lipoprotein apheresis.

hite, 7% asian, 3% black, and 9% other. forty-four (54%) evkeeza-treated patients had hofh. patients received evkeeza as add-on therapy to other lipid-lowering therapies, including maximally tolerated statin, ezetimibe, pcsk9 inhibitors, lomitapide, and apheresis. adverse reactions led to discontinuation of treatment in 2 (2%) patients treated with evkeeza, including 1 case of anaphylaxis, and 1 (2%) patient who received placebo. the most common adverse reactions (reported in greater than 3% of evkeeza-treated patients and more frequently than in placebo) are shown in table 1. table 1: adverse reactions occurring in >3% of patients treated with evkeeza and greater than placebo in 24-week, pooled, placebo-controlled trials adverse reactions placebo (n = 54) % evkeeza (n = 81) % nasopharyngitis 13% 16% influenza like illness 6% 7% dizziness 0% 6% rhinorrhea 0% 5% nausea 2% 5% pain in extremity 0% 4% asthenia 0% 4% other adverse reactions occurring in less than 3% of patients treated with evkeeza and greater than placebo included constipation, upper respiratory tract infection, nasal congestion, and abdominal pain. transient, mild to moderate decreases in diastolic blood pressure and increases in heart rate occurred in clinical trials of evkeeza infusion but did not require intervention and resolved post-infusion. serious hypersensitivity reactions anaphylaxis was reported in 1 (1%) patient treated with evkeeza and 0% in patients who received placebo. infusion reactions infusion reactions were reported in 6 (7%) patients treated with evkeeza and in 2 (4%) patients who received placebo. the following infusion reactions occurred in evkeeza-treated patients: infusion site pruritus, pyrexia, muscular weakness, nausea, and nasal congestion. 6.2 immunogenicity as with all therapeutic proteins, there is potential for immunogenicity. the detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. for these reasons, comparison of the incidence of antibodies to evkeeza in the studies described below with the incidence of antibodies in other studies or to other products may be misleading. no patients developed treatment-emergent antibodies to evkeeza.

serum concentrations were observed in fetal rabbit and rat sera at birth, indicating that evinacumab-dgnb, like other igg antibodies, crosses the placental barrier (see data ). advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. if a patient becomes pregnant while receiving evkeeza, healthcare providers should report evkeeza exposure by calling 1-833-385-3392. data animal data in an embryo-fetal development study in pregnant rabbits, evinacumab-dgnb was administered subcutaneously at doses of 1, 5, 10 and 30 mg/kg every 3 days (q3d) during the period of organogenesis from gestation day 7 to day 19. evinacumab-dgnb was teratogenic in rabbits, causing domed head, dilation of the lateral and third ventricles of the brain, and flexed fore/hind paws at maternal evinacumab-dgnb exposures below human exposure at the mrhd of 15 mg/kg every 4 weeks, based on auc. other fetal malformations, consisting of irregular and abnormal ossification in the skull, palate, and metacarpal, and enlarged anterior and/or posterior fontanelles occurred and were consistent with significant maternal toxicity (including early deaths due to abortion and premature delivery at all doses, reduction in maternal body weight gains, and reduced maternal food consumption). increased incidences of post-implantation losses, resorptions (total, early, and late), and decreased fetal body weight were also consistent with maternal toxicity. evinacumab-dgnb was present in the sera of fetuses born from mothers at 10 and 30 mg/kg/q3d at levels higher than in maternal serum. in an embryo-fetal development study in pregnant rats, evinacumab-dgnb was administered subcutaneously at doses of 5, 10, 30 and 100 mg/kg/q3d during the period of organogenesis from gestation day 6 to day 18. maternal exposures to evinacumab-dgnb were below the human exposure measured at the mrhd. evinacumab-dgnb resulted in unexplained maternal deaths at 100 mg/kg/q3d. evinacumab-dgnb crossed the placenta and was present at ratios (c fetal /c maternal ) ranging from 0.42 to 0.65. no adverse effects on embryofetal development were observed at any dose. in a combined fertility, embryofetal, and pre- and postnatal development study, female rats were administered evinacumab-dgnb via subcutaneous injection at doses of 30 and 100 mg/kg/q3d beginning 2 weeks prior to mating and continuing to gestation day 21 or lactation day 21. mean maternal systemic exposures were below the human exposure at the mrhd throughout the study. no maternal or developmental toxicity was observed. 8.2 lactation risk summary there are no data on the presence of evinacumab-dgnb in human milk or animal milk, the effects on the breastfed infant, or the effects on milk production. maternal igg is known to be present in human milk. the effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to evinacumab-dgnb are unknown. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for evkeeza and any potential adverse effects on the breastfed infant from evkeeza or from the underlying maternal condition. 8.3 females and males of reproductive potential pregnancy testing consider pregnancy testing in patients who may become pregnant prior to starting treatment with evkeeza [see warnings and precautions (5.2) and use in specific populations (8.1) ]. contraception females based on animal studies, evkeeza may cause fetal harm when administered to pregnant patients [see use in specific populations (8.1) ] . patients who may become pregnant should use effective contraception during treatment with evkeeza and for at least 5 months following the last dose of evkeeza. 8.4 pediatric use the safety and effectiveness of evkeeza as an adjunct to other ldl-c-lowering therapies for the treatment of hofh have been established in pediatric patients aged 12 years and older. use of evkeeza for this indication is supported by evidence from adequate and well-controlled trials in adults with additional efficacy and safety data in pediatric patients aged 12 years and older [see adverse reactions (6.1) and clinical studies (14) ]. the safety and effectiveness of evkeeza have not been established in pediatric patients with hofh who are younger than 12 years old. 8.5 geriatric use clinical studies of evkeeza did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

erved in fetal rabbit and rat sera at birth, indicating that evinacumab-dgnb, like other igg antibodies, crosses the placental barrier (see data ). advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. if a patient becomes pregnant while receiving evkeeza, healthcare providers should report evkeeza exposure by calling 1-833-385-3392. data animal data in an embryo-fetal development study in pregnant rabbits, evinacumab-dgnb was administered subcutaneously at doses of 1, 5, 10 and 30 mg/kg every 3 days (q3d) during the period of organogenesis from gestation day 7 to day 19. evinacumab-dgnb was teratogenic in rabbits, causing domed head, dilation of the lateral and third ventricles of the brain, and flexed fore/hind paws at maternal evinacumab-dgnb exposures below human exposure at the mrhd of 15 mg/kg every 4 weeks, based on auc. other fetal malformations, consisting of irregular and abnormal ossification in the skull, palate, and metacarpal, and enlarged anterior and/or posterior fontanelles occurred and were consistent with significant maternal toxicity (including early deaths due to abortion and premature delivery at all doses, reduction in maternal body weight gains, and reduced maternal food consumption). increased incidences of post-implantation losses, resorptions (total, early, and late), and decreased fetal body weight were also consistent with maternal toxicity. evinacumab-dgnb was present in the sera of fetuses born from mothers at 10 and 30 mg/kg/q3d at levels higher than in maternal serum. in an embryo-fetal development study in pregnant rats, evinacumab-dgnb was administered subcutaneously at doses of 5, 10, 30 and 100 mg/kg/q3d during the period of organogenesis from gestation day 6 to day 18. maternal exposures to evinacumab-dgnb were below the human exposure measured at the mrhd. evinacumab-dgnb resulted in unexplained maternal deaths at 100 mg/kg/q3d. evinacumab-dgnb crossed the placenta and was present at ratios (c fetal /c maternal ) ranging from 0.42 to 0.65. no adverse effects on embryofetal development were observed at any dose. in a combined fertility, embryofetal, and pre- and postnatal development study, female rats were administered evinacumab-dgnb via subcutaneous injection at doses of 30 and 100 mg/kg/q3d beginning 2 weeks prior to mating and continuing to gestation day 21 or lactation day 21. mean maternal systemic exposures were below the human exposure at the mrhd throughout the study. no maternal or developmental toxicity was observed.

scribed in this section are presented following administration of evinacumab-dgnb 15 mg/kg intravenously every 4 weeks, unless otherwise specified. steady-state is reached after 4 doses, and the accumulation ratio is 2. according to population pharmacokinetic modeling, the mean (standard deviation) steady-state trough concentration is 241 (96.5) mg/l, whereas the mean (standard deviation) c max at the end of infusion is 689 (157) mg/l. due to non-linear clearance, a 4.3-fold increase in area under the concentration-time curve at steady-state (auc tau.ss ) for a 3-fold increase in evinacumab-dgnb dose up to 15 mg/kg iv every 4 weeks was predicted in patients with hofh. distribution the total volume of distribution estimated via population pharmacokinetic analysis was approximately 4.8 l. elimination evinacumab-dgnb elimination is mediated via parallel linear and non-linear pathways. at higher concentrations, evinacumab-dgnb elimination is primarily through a non-saturable proteolytic pathway, whereas at lower concentrations, the non-linear, saturable angptl3 target-mediated elimination predominates. the elimination half-life is a function of serum evinacumab-dgnb concentrations and is not a constant. based on a population pharmacokinetic analysis, the median time for serum evinacumab-dgnb concentrations to decrease below the lower limit of quantitation (78 ng/ml) is 19 weeks after the last steady-state dose of 15 mg/kg iv every 4 weeks. metabolism the exact pathway through which evinacumab-dgnb is metabolized has not been characterized. as a human monoclonal igg4 antibody, evinacumab-dgnb is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous igg. excretion evinacumab-dgnb, a monoclonal antibody, is not likely to undergo renal excretion. specific populations a population pk analysis conducted on data from 183 healthy subjects and 95 patients with hofh suggests that the following factors have no clinically significant effect on the exposure of evinacumab-dgnb: age (12 to 75 years), gender, body weight (42 to 152 kg), and race (white, asian, black, and other). pediatric patients a 15-year-old patient with hofh received evinacumab-dgnb at 15 mg/kg iv every 4 weeks. steady-state trough and end-of-infusion concentrations were within the range observed in adult patients. patients with renal impairment observed trough serum evinacumab-dgnb concentrations at steady-state were comparable between patients with mild or moderate renal impairment and patients with normal renal function. no data are available in patients with severe renal impairment. patients with hepatic impairment no data are available in patients with hepatic impairment . drug interaction studies drug interaction studies have not been conducted with evinacumab-dgnb. in a clinical trial, the concentrations of statins (atorvastatin, rosuvastatin, simvastatin) were not meaningfully altered in patients taking statins prior to and post administration of evinacumab-dgnb. concentrations of evinacumab-dgnb were comparable in patients with hofh taking or not taking background lipid-lowering therapy.

ion is primarily through a non-saturable proteolytic pathway, whereas at lower concentrations, the non-linear, saturable angptl3 target-mediated elimination predominates. the elimination half-life is a function of serum evinacumab-dgnb concentrations and is not a constant. based on a population pharmacokinetic analysis, the median time for serum evinacumab-dgnb concentrations to decrease below the lower limit of quantitation (78 ng/ml) is 19 weeks after the last steady-state dose of 15 mg/kg iv every 4 weeks. metabolism the exact pathway through which evinacumab-dgnb is metabolized has not been characterized. as a human monoclonal igg4 antibody, evinacumab-dgnb is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous igg. excretion evinacumab-dgnb, a monoclonal antibody, is not likely to undergo renal excretion. specific populations a population pk analysis conducted on data from 183 healthy subjects and 95 patients with hofh suggests that the following factors have no clinically significant effect on the exposure of evinacumab-dgnb: age (12 to 75 years), gender, body weight (42 to 152 kg), and race (white, asian, black, and other). pediatric patients a 15-year-old patient with hofh received evinacumab-dgnb at 15 mg/kg iv every 4 weeks. steady-state trough and end-of-infusion concentrations were within the range observed in adult patients. patients with renal impairment observed trough serum evinacumab-dgnb concentrations at steady-state were comparable between patients with mild or moderate renal impairment and patients with normal renal function. no data are available in patients with severe renal impairment. patients with hepatic impairment no data are available in patients with hepatic impairment . drug interaction studies drug interaction studies have not been conducted with evinacumab-dgnb. in a clinical trial, the concentrations of statins (atorvastatin, rosuvastatin, simvastatin) were not meaningfully altered in patients taking statins prior to and post administration of evinacumab-dgnb. concentrations of evinacumab-dgnb were comparable in patients with hofh taking or not taking background lipid-lowering therapy.

g/kg/q3d beginning 2 weeks prior to mating, no adverse effect on female fertility were observed at any dose. exposures to evinacumab-dgnb represented less than the human exposure at the mrhd, based on auc. no effects on male fertility were observed with evinacumab-dgnb administration to male rabbits for 40 days prior to mating with treatment-naïve females. evinacumab-dgnb was administered to male rabbits intravenously at 100 and 300 mg/kg/q5d, representing exposures 2- and 5-times, respectively, the human exposure at the mrhd, based on auc.

prior to mating, no adverse effect on female fertility were observed at any dose. exposures to evinacumab-dgnb represented less than the human exposure at the mrhd, based on auc. no effects on male fertility were observed with evinacumab-dgnb administration to male rabbits for 40 days prior to mating with treatment-naïve females. evinacumab-dgnb was administered to male rabbits intravenously at 100 and 300 mg/kg/q5d, representing exposures 2- and 5-times, respectively, the human exposure at the mrhd, based on auc.

s of age or evidence of tc >250 mg/dl in both parents. in this trial, 40% (26 of 65) patients had limited ldl receptor (ldlr) function, defined by either <15% receptor function by in vitro assays or by genetic variants likely to result in minimal to no ldlr function by mutation analysis. the mean ldl-c at baseline was 255 mg/dl. in patients with limited ldlr function, the mean ldl-c at baseline was 307 mg/dl. at baseline, 94% of patients were on statins, 75% on ezetimibe, 77% on a pcsk9 inhibitor antibody, 22% on lomitapide, and 34% were receiving lipoprotein apheresis. the mean age at baseline was 42 years (range 12 to 75) with 12% ≥65 years old; 54% women, 3% hispanic, 74% white, 15% asian, 3% black, and 8% other or not reported. the primary efficacy endpoint was percent change in ldl-c from baseline to week 24. at week 24, the least squares (ls) mean treatment difference between evkeeza and placebo in mean percent change in ldl-c from baseline was −49% (95% confidence interval: −65% to −33%; p <0.0001). after 24 weeks of open-label evkeeza treatment (week 24 to week 48), the observed ldl-c reduction from baseline was similar in patients who crossed over from placebo to evkeeza and was maintained in patients who remained on evkeeza for 48 weeks. for efficacy results see table 2 . table 2: lipid parameters in patients with hofh on other lipid-lowering therapies in study elipse-hofh ldl-c apob non-hdl-c tc tg neither tg nor hdl-c were pre-specified in the hypothesis testing hdl-c abbreviations: hofh=homozygous familial hypercholesterolemia, itt=intent-to-treat, ls mean=least squares mean, n=number of randomized patients, ci=confidence interval baseline (mean), mg/dl (n=65) 255 171 278 322 124 44 ls mean: evkeeza (n = 43) -47% -41% -50% -47% -55% -30% mean percent change, based on safety population (evkeeza, n=44; placebo, n=20); hdl-c is presented for completeness but was not an efficacy endpoint that was statistically analyzed. one subject in the placebo group discontinued the study before week 24. the treatment difference and 95% confidence interval (ci) were estimated using a mixed model repeated measures analysis. ls mean: placebo (n = 22) +2% -5% +2% +1% -5% +1% ls mean difference from placebo (95% ci) -49% (-65 to -33) -37% (-49 to -25) -52% (-65 to -39) -48% (-59 to -38) -50% (-66 to -35) - the ls mean ldl-c percent changes over time are presented in figure 1. figure 1: calculated ldl-c ls mean percent change from baseline over time through week 24 in study elipse-hofh abbreviations: ls mean=least squares mean, hofh=homozygous familial hypercholesterolemia, dbtp=double-blind treatment period, se=standard error at week 24, the observed reduction in ldl-c with evkeeza was similar across predefined subgroups, including age, sex, limited ldlr activity, concomitant treatment with lipoprotein apheresis, and concomitant background lipid-lowering medications (statins, ezetimibe, pcsk9 inhibitor antibodies, and lomitapide). figure 1 pediatric patients with hofh in elipse-hofh, 1 pediatric patient received 15 mg/kg iv of evkeeza every 4 weeks, and 1 pediatric patient received placebo, as an adjunct to other lipid-lowering therapies (e.g., statins, ezetimibe, pcsk9 inhibitor antibodies and lipoprotein apheresis). both patients had null/null variants in the ldlr. at week 24, the percent change in ldl-c with evkeeza was - 73% and with placebo was +60%. in an open-label extension study, 13 pediatric patients with hofh (12 to 17 years of age) received 15 mg/kg iv of evkeeza every 4 weeks as an adjunct to other lipid-lowering therapies (e.g., statins, ezetimibe, pcsk9 inhibitor antibodies and lipoprotein apheresis) for a median treatment duration of 33 weeks. the mean percent change from baseline in ldl-c at week 24 was -52% in the 9 patients who completed treatment and had a lipid assessment at week 24. overall, the effect of evinacumab-dgnb on lipid parameters in pediatric patients with hofh was generally similar to that seen in adults with hofh.

ider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. evkeeza may harm your unborn baby. tell your healthcare provider if you become pregnant while using evkeeza. people who are able to become pregnant: your healthcare provider may do a pregnancy test before you start treatment with evkeeza you should use an effective method of birth control during treatment and for at least 5 months after the last dose of evkeeza. talk with your healthcare provider about birth control methods that you can use during this time. are breastfeeding or plan to breastfeed. it is not known if evkeeza passes into your breast milk. you and your healthcare provider should decide if you will receive evkeeza or breastfeed. tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. how will i receive evkeeza? your healthcare provider will give you evkeeza into your veins through an intravenous (iv) line over 60 minutes. evkeeza should be given every month (4 weeks). if you miss any infusion appointments, call your healthcare provider as soon as possible to reschedule. your healthcare provider may slow down your infusion rate, temporarily stop, or permanently stop treatment with evkeeza if you have certain side effects. see " what are the possible side effects of evkeeza? " your healthcare provider may prescribe other cholesterol-lowering medicines, to use with evkeeza. use the other prescribed medicines exactly as your healthcare provider tells you to. what are the possible side effects of evkeeza? evkeeza can cause serious side effects, including: allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. tell your healthcare provider right away if you get any of the following symptoms: swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe breathing problems or wheezing feeling dizzy or fainting rash, hives itching the most common side effects of evkeeza include: symptoms of the common cold flu like symptoms dizziness pain in legs or arms nausea decreased energy tell your healthcare provider if you have any side effect that bothers you or that does not go away. these are not all of the possible side effects of evkeeza. call your doctor for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. general information about the safe and effective use of evkeeza. medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. if you would like more information about evkeeza, talk with your healthcare provider. you can ask your healthcare provider for information about evkeeza that is written for health professionals. what are the ingredients in evkeeza? active ingredient: evinacumab-dgnb inactive ingredients: l-arginine hydrochloride, l-histidine, l-histidine monohydrochloride monohydrate, l-proline, polysorbate 80, and water for injection, usp. manufactured by: regeneron pharmaceuticals, inc. 777 old saw mill river road tarrytown, ny 10591-6707 u.s. license no. 1760 © 2021 regeneron pharmaceuticals, inc. all rights reserved. for more information about evkeeza, go to www.evkeeza.com or call 1-833-evkeeza (833-385-3392)